Literature DB >> 31021193

CRISPR-Cas9-Mediated Correction of the 1.02 kb Common Deletion in CLN3 in Induced Pluripotent Stem Cells from Patients with Batten Disease.

Erin R Burnight1,2, Laura R Bohrer1,2, Joseph C Giacalone1,2, Darcey L Klaahsen1,2, Heather T Daggett1,2, Jade S East1,2, Robert A Madumba1,2, Kristan S Worthington1,3, Robert F Mullins1,2, Edwin M Stone1,2, Budd A Tucker1,2, Luke A Wiley1,2.   

Abstract

Juvenile neuronal ceroid lipofuscinosis (Batten disease) is a rare progressive neurodegenerative disorder caused by mutations in CLN3. Patients present with early-onset retinal degeneration, followed by epilepsy, progressive motor deficits, cognitive decline, and premature death. Approximately 85% of individuals with Batten disease harbor at least one allele containing a 1.02 kb genomic deletion spanning exons 7 and 8. This study demonstrates CRISPR-Cas9-based homology-dependent repair of this mutation in induced pluripotent stem cells generated from two independent patients: one homozygous and one compound heterozygous for the 1.02 kb deletion. Our strategy included delivery of a construct that carried >3 kb of DNA: wild-type CLN3 sequence and a LoxP-flanked, puromycin resistance cassette for positive selection. This strategy resulted in correction at the genomic DNA and mRNA levels in the two independent patient lines. These CRISPR-corrected isogenic cell lines will be a valuable tool for disease modeling and autologous retinal cell replacement.

Entities:  

Year:  2018        PMID: 31021193      PMCID: PMC6319325          DOI: 10.1089/crispr.2017.0015

Source DB:  PubMed          Journal:  CRISPR J        ISSN: 2573-1599


  42 in total

1.  Two motifs target Batten disease protein CLN3 to lysosomes in transfected nonneuronal and neuronal cells.

Authors:  Aija Kyttälä; Gudrun Ihrke; Jouni Vesa; Michael J Schell; J Paul Luzio
Journal:  Mol Biol Cell       Date:  2003-12-29       Impact factor: 4.138

2.  Using Patient-Specific Induced Pluripotent Stem Cells and Wild-Type Mice to Develop a Gene Augmentation-Based Strategy to Treat CLN3-Associated Retinal Degeneration.

Authors:  Luke A Wiley; Erin R Burnight; Arlene V Drack; Bailey B Banach; Dalyz Ochoa; Cathryn M Cranston; Robert A Madumba; Jade S East; Robert F Mullins; Edwin M Stone; Budd A Tucker
Journal:  Hum Gene Ther       Date:  2016-07-11       Impact factor: 5.695

3.  Gene editing using ssODNs with engineered endonucleases.

Authors:  Fuqiang Chen; Shondra M Pruett-Miller; Gregory D Davis
Journal:  Methods Mol Biol       Date:  2015

4.  Patient-specific induced pluripotent stem cells to evaluate the pathophysiology of TRNT1-associated Retinitis pigmentosa.

Authors:  Tasneem P Sharma; Luke A Wiley; S Scott Whitmore; Kristin R Anfinson; Cathryn M Cranston; Douglas J Oppedal; Heather T Daggett; Robert F Mullins; Budd A Tucker; Edwin M Stone
Journal:  Stem Cell Res       Date:  2017-03-18       Impact factor: 2.020

5.  DNA targeting specificity of RNA-guided Cas9 nucleases.

Authors:  Patrick D Hsu; David A Scott; Joshua A Weinstein; F Ann Ran; Silvana Konermann; Vineeta Agarwala; Yinqing Li; Eli J Fine; Xuebing Wu; Ophir Shalem; Thomas J Cradick; Luciano A Marraffini; Gang Bao; Feng Zhang
Journal:  Nat Biotechnol       Date:  2013-07-21       Impact factor: 54.908

6.  Characterization of Cln3p, the gene product responsible for juvenile neuronal ceroid lipofuscinosis, as a lysosomal integral membrane glycoprotein.

Authors:  Junji Ezaki; Mitsue Takeda-Ezaki; Masato Koike; Yoshiyuki Ohsawa; Hikari Taka; Reiko Mineki; Kimie Murayama; Yasuo Uchiyama; Takashi Ueno; Eiki Kominami
Journal:  J Neurochem       Date:  2003-12       Impact factor: 5.372

7.  GUIDE-seq enables genome-wide profiling of off-target cleavage by CRISPR-Cas nucleases.

Authors:  Shengdar Q Tsai; Zongli Zheng; Nhu T Nguyen; Matthew Liebers; Ved V Topkar; Vishal Thapar; Nicolas Wyvekens; Cyd Khayter; A John Iafrate; Long P Le; Martin J Aryee; J Keith Joung
Journal:  Nat Biotechnol       Date:  2014-12-16       Impact factor: 54.908

8.  In vivo genome editing using Staphylococcus aureus Cas9.

Authors:  F Ann Ran; Le Cong; Winston X Yan; David A Scott; Jonathan S Gootenberg; Andrea J Kriz; Bernd Zetsche; Ophir Shalem; Xuebing Wu; Kira S Makarova; Eugene V Koonin; Phillip A Sharp; Feng Zhang
Journal:  Nature       Date:  2015-04-01       Impact factor: 49.962

9.  CIRCLE-seq: a highly sensitive in vitro screen for genome-wide CRISPR-Cas9 nuclease off-targets.

Authors:  Shengdar Q Tsai; Nhu T Nguyen; Jose Malagon-Lopez; Ved V Topkar; Martin J Aryee; J Keith Joung
Journal:  Nat Methods       Date:  2017-05-01       Impact factor: 28.547

10.  Evaluation of off-target and on-target scoring algorithms and integration into the guide RNA selection tool CRISPOR.

Authors:  Maximilian Haeussler; Kai Schönig; Hélène Eckert; Alexis Eschstruth; Joffrey Mianné; Jean-Baptiste Renaud; Sylvie Schneider-Maunoury; Alena Shkumatava; Lydia Teboul; Jim Kent; Jean-Stephane Joly; Jean-Paul Concordet
Journal:  Genome Biol       Date:  2016-07-05       Impact factor: 13.583

View more
  8 in total

Review 1.  CRISPR-Cas9 genome engineering: Treating inherited retinal degeneration.

Authors:  Erin R Burnight; Joseph C Giacalone; Jessica A Cooke; Jessica R Thompson; Laura R Bohrer; Kathleen R Chirco; Arlene V Drack; John H Fingert; Kristan S Worthington; Luke A Wiley; Robert F Mullins; Edwin M Stone; Budd A Tucker
Journal:  Prog Retin Eye Res       Date:  2018-03-22       Impact factor: 21.198

2.  In Vitro Models of the Human Blood-Brain Barrier Utilising Human Induced Pluripotent Stem Cells: Opportunities and Challenges.

Authors:  Iqra Pervaiz; Abraham J Al-Ahmad
Journal:  Methods Mol Biol       Date:  2022

3.  Correction of NR2E3 Associated Enhanced S-cone Syndrome Patient-specific iPSCs using CRISPR-Cas9.

Authors:  Laura R Bohrer; Luke A Wiley; Erin R Burnight; Jessica A Cooke; Joseph C Giacalone; Kristin R Anfinson; Jeaneen L Andorf; Robert F Mullins; Edwin M Stone; Budd A Tucker
Journal:  Genes (Basel)       Date:  2019-04-05       Impact factor: 4.096

Review 4.  Patient-Derived Induced Pluripotent Stem Cell Models for Phenotypic Screening in the Neuronal Ceroid Lipofuscinoses.

Authors:  Ahmed Morsy; Angelica V Carmona; Paul C Trippier
Journal:  Molecules       Date:  2021-10-15       Impact factor: 4.411

5.  Robust genome and RNA editing via CRISPR nucleases in PiggyBac systems.

Authors:  Yuqian Jiang; Rachel Catherine Hoenisch; Yun Chang; Xiaoping Bao; Craig E Cameron; Xiaojun Lance Lian
Journal:  Bioact Mater       Date:  2022-02-07

Review 6.  CRISPR and iPSCs: Recent Developments and Future Perspectives in Neurodegenerative Disease Modelling, Research, and Therapeutics.

Authors:  Tirthankar Sen; Rajkumar P Thummer
Journal:  Neurotox Res       Date:  2022-08-31       Impact factor: 3.978

Review 7.  A Link between Genetic Disorders and Cellular Impairment, Using Human Induced Pluripotent Stem Cells to Reveal the Functional Consequences of Copy Number Variations in the Central Nervous System-A Close Look at Chromosome 15.

Authors:  Alessia Casamassa; Daniela Ferrari; Maurizio Gelati; Massimo Carella; Angelo Luigi Vescovi; Jessica Rosati
Journal:  Int J Mol Sci       Date:  2020-03-09       Impact factor: 5.923

8.  CLN3, at the crossroads of endocytic trafficking.

Authors:  Susan L Cotman; Stéphane Lefrancois
Journal:  Neurosci Lett       Date:  2021-07-16       Impact factor: 3.197

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.